All In MedTech

FDA Clearance Tracker · P020050-S006

WAVELIGHT EX500 LASER SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 23, 2011 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 23, 2011

Approved

Time to decision

233 days

Received Apr 4, 2011. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P020050-S006
Device name
WAVELIGHT EX500 LASER SYSTEM
Applicant location
Fort Worth, TX
Received
Apr 4, 2011
Decided
Nov 23, 2011
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P020050

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR INCREASED PULSE FREQUENCY FROM 400 TO 500 HZ, A NEW LASER HEAD, A NEW HOUSING WITH GREATER INTEGRATION OF ACCESSORIES, MODIFIED LASER PULSE TEMPORAL PARAMETERS, NEW EYETRACKER, NEW SCANNER, REMODELED USER INTERFACE, ADDITION OF NETWORKING CAPABILITY, ANDMODIFIED SOFTWARE. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME WAVELIGHT EX500 LASER SYSTEM AND IS INDICATED FOR LASER ASSISTED IN SITU KERATOMILEUSIS (LASIK) FOR:1) THE REDUCTION OR ELIMINATION OF MYOPIA OF UP TO -12.0 DIOPTERS (D) OF SPHERE AND UP TO - 6.0 D OF ASTIGMATISM AT THE SPECTACLE PLANE IN PATIENTS WHO ARE 18 YEARS OF AGE OR OLDER WITH DOCUMENTATION OF A STABLE MANIFEST REFRACTION DEFINED AS <= 0.50 D OF PREOPERATIVESPHERICAL EQUIVALENT SHIFT OVER ONE YEAR PRIOR TO SURGERY;2) THE REDUCTION OR ELIMINATION OF HYPEROPIC REFRACTIVE ERRORS UP TO +6.0 D OF SPHERE WITH AND WITHOUT ASTIGMATIC REFRACTIVE ERRORS UP TO 5.0 D AT THE SPECTACLE PLANE, WITH A MAXIMUM MANIFEST REFRACTION SPHERICAL EQUIVALENT (MRSE) OF +6.0 D IN PATIENTS WHO ARE 18 YEARS OF AGE OR OLDER WITH DOCUMENTATION OF STABLE MANIFEST REFRACTION DEFINED AS<= 0.50 D OF PREOPERATIVE SPHERICAL EQUIVALENT SHIFT OVER ONE YEAR PRIOR TO SURGERY, EXCLUSIVE OF CHANGES DUE TO UNMASKING LATENT HYPEROPIA;3) THE REDUCTION OR ELIMINATION OF NATURALLY OCCURRING MIXED ASTIGMATISM OF UP TO 6.00 D AT THE SPECTACLE PLANE IN PATIENTS WHO ARE 21 YEARS OF AGE OR OLDER WITH DOCUMENTATION OF A STABLE MANIFEST REFRACTION DEFINED AS <= 0.50 D PREOPERATIVE SPHERICAL EQUIVALENT SHIFT OVER ONE YEAR PRIOR TO SURGERY; AND 4) THE WAVEFRONT-GUIDED (WFG) REDUCTION OR ELIMINATION OF UP TO -7.00 D OF SPHERICAL EQUIVALENT MYOPIA OR MYOPIA WITH ASTIGMATISM, WITH UP TO -7.00 D OF SPHERICAL COMPONENT AND UP TO 3.00 D OF ASTIGMATIC COMPONENT AT THE SPECTACLE PLANE IN PATIENTS WHO ARE 18 YEARS OF AGE OR OLDER WITH DOCUMENTATION OF A STABLE MANIFEST REFRACTION DEFINED AS <= 0.50 D OF PREOPERATIVE SPHERICAL SHIFT OVER ONE YEAR PRIOR TO SURGERY.

Source documents

Other decisions for Alcon Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.